Cargando…

Correlation of adverse effects and antibody responses following homologous and heterologous COVID19 prime-boost vaccinations

Mostrar otras versiones (1)

BACKGROUND: Studies correlating reactogenicity and immunogenicity of COVID-19 vaccines are limited to BNT162b2, with inconsistent results. We investigated whether adverse reactions after other COVID-19 vaccines reliably predict humoral responses. METHODS: Adult volunteers were recruited for homologo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Aristine, Hsieh, Ming-Ju, Chang, Sui-Yuan, Ieong, Si-Man, Cheng, Chien-Yu, Sheng, Wang-Huei, Chang, Shan-Chwen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Formosan Medical Association, Elsevier 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750882/ https://www.ncbi.nlm.nih.gov/pubmed/36564299 http://dx.doi.org/10.1016/j.jfma.2022.12.002

Ejemplares similares

Correlation of adverse effects and antibody responses following homologous and heterologous COVID-19 prime-boost vaccinations
por: Cheng, Aristine, et al.
Publicado: (2023)

Serological response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 prime-boost vaccination with a twelve-week interval
por: Sheng, Wang-Huei, et al.
Publicado: (2023)

Adverse effects and antibody responses following homologous and heterologous COVID19 prime-boost vaccinations
por: Kleebayoon, Amnuay, et al.
Publicado: (2023)

Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination
por: Sheng, Wang-Huei, et al.
Publicado: (2022)

Safety and antibody response of recipients who unexpectedly received undiluted prime dose of BNT162b2 COVID-19 vaccine in Taiwan
por: Sheng, Wang-Huei, et al.
Publicado: (2023)

Serological response after COVID-19 mRNA-1273 booster dose in immunocompromised patients, Taiwan, July to August 2021
por: Lin, Kuan-Yin, et al.
Publicado: (2022)

Immunogenicity and Safety of Homologous and Heterologous Prime–Boost Immunization with COVID-19 Vaccine: Systematic Review and Meta-Analysis
por: Cheng, Haoyue, et al.
Publicado: (2022)

Heterologous prime-boost with A(H5N1) pandemic influenza vaccines induces broader cross-clade antibody responses than homologous prime-boost
por: Levine, Min Z., et al.
Publicado: (2019)

Heterologous Prime-Boost Vaccination with Commercial FMD Vaccines Elicits a Broader Immune Response than Homologous Prime-Boost Vaccination in Pigs
por: Kim, Jaejo, et al.
Publicado: (2023)

The efficacy of the prime-boost regimen for heterologous infectious bronchitis vaccines mandates the administration of homologous vaccines
por: Al-Kubati, Anwar A. G., et al.
Publicado: (2022)

Heterologous prime boost COVID 19 vaccination
por: Launay, O., et al.
Publicado: (2022)

Antibody response induced by the boost overdose during COVID-19 heterologous prime-boost vaccination strategy
por: Raposo, Francisco, et al.
Publicado: (2021)

Heterologous Boosting With Listeria-Based Recombinant Strains in BCG-Primed Mice Improved Protection Against Pulmonary Mycobacterial Infection
por: Liu, Si-Jing, et al.
Publicado: (2020)

Immunogenicity and safety of third-dose mRNA COVID-19 vaccines in healthy adults previously vaccinated with two doses of the ChAdOx1 vaccine
por: Sheng, Wang-Huei, et al.
Publicado: (2023)

Durability of Heterologous and Homologous COVID-19 Vaccine Boosts
por: Tan, C. Sabrina, et al.
Publicado: (2022)

Immune response of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA COVID-19 vaccines in immunocompromised patients
por: Chu, Chang, et al.
Publicado: (2023)

The Effects of Heterologous Immunization with Prime-Boost COVID-19 Vaccination against SARS-CoV-2
por: Ho, Tzu-Chuan, et al.
Publicado: (2021)

Heterologous Prime-Boost Combinations Highlight the Crucial Role of Adjuvant in Priming the Immune System
por: Ciabattini, Annalisa, et al.
Publicado: (2018)

Heterologous prime-boost: an important candidate immunization strategy against Tembusu virus
por: Pan, Yuting, et al.
Publicado: (2020)

Heterologous Prime-Boost Vaccination with Inactivated Influenza Viruses Induces More Effective Cross-Protection than Homologous Repeat Vaccination
por: Bhatnagar, Noopur, et al.
Publicado: (2023)

Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine
por: Nguyen, Thuy Trang, et al.
Publicado: (2022)

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
por: Shaw, Robert H, et al.
Publicado: (2021)

Heterologous prime-boost vaccination against COVID-19: is it safe and reliable?
por: Choudhary, Om Prakash, et al.
Publicado: (2021)

Comparison of homologous and heterologous prime-boost vaccine approaches using Modified Vaccinia Ankara and soluble protein to induce neutralizing antibodies by the human cytomegalovirus pentamer complex in mice
por: Chiuppesi, Flavia, et al.
Publicado: (2017)

Cross-Reactivity Conferred by Homologous and Heterologous Prime-Boost A/H5 Influenza Vaccination Strategies in Humans: A Literature Review
por: Kok, Adinda, et al.
Publicado: (2021)

1441. Doses of 13-Valent Conjugated Pneumococcal Vaccine (PCV13) for Patients With Multiple Myeloma (MM)
por: Sun, Hsin-Yun, et al.
Publicado: (2018)

1360. Disseminated Mycobacterium abscessus Infections in Patients with Neutralizing Anti-interferon-gamma Autoantibodies Treated with Rifabutin-based Combination Regimens
por: Cheng, Aristine, et al.
Publicado: (2019)

Potency of an HIV-SAM™ vaccine in a heterologous prime-boost vaccination regimen
por: Banerjee, K, et al.
Publicado: (2012)

Exploring heterologous prime-boost vaccination approaches to enhance influenza control in pigs
por: Li, Chong, et al.
Publicado: (2020)

Assessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV
por: Chapman, Ros, et al.
Publicado: (2021)

Is heterologous prime-boost COVID-19 vaccination a concern or an opportunity for Ethiopia?
por: Gelanew, Tesfaye, et al.
Publicado: (2023)

An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines
por: Vallée, Alexandre, et al.
Publicado: (2021)

Reactogenicity after heterologous and homologous COVID-19 prime-boost vaccination regimens: descriptive interim results of a comparative observational cohort study
por: Warkentin, Lisette, et al.
Publicado: (2022)

Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review
por: Lv, Jingjing, et al.
Publicado: (2022)

In-depth analysis of T cell immunity and antibody responses in heterologous prime-boost-boost vaccine regimens against SARS-CoV-2 and Omicron variant
por: Heinen, Natalie, et al.
Publicado: (2022)

Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals
por: Mallah, Saad I., et al.
Publicado: (2023)

Immunogenicity and Protective Efficacy of Brugia malayi Heavy Chain Myosin as Homologous DNA, Protein and Heterologous DNA/Protein Prime Boost Vaccine in Rodent Model
por: Gupta, Jyoti, et al.
Publicado: (2015)

Heterologous prime-boost regimens with HAdV-5 and NDV vectors elicit stronger immune responses to Ebola virus than homologous regimens in mice
por: Zhao, Wei, et al.
Publicado: (2021)

Homologous versus Heterologous prime-boost COVID-19 Vaccination in autologous hematopoietic stem cell transplantation recipients: a blinded randomized controlled trial
por: Sharifi Aliabadi, Leyla, et al.
Publicado: (2023)

Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials
por: Brown, Scott A., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_1c5nkqbvikfhpgv7sm3gglmj1j